ATE409031T1 - Tablettenformulierungen von venlafaxin mit verzögerter freisetzung - Google Patents

Tablettenformulierungen von venlafaxin mit verzögerter freisetzung

Info

Publication number: ATE409031T1
Authority: AT; Austria
Prior art keywords: venlafaxine; sustained; release tablet; tablet formulations; relates
Prior art date: 2003-10-13

Application number

AT04765928T

Other languages

English (en)

Inventor

Michael Rowley

Angela Potts

Edward Sims

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-13

Filing date

2004-10-12

Publication date

2008-10-15

2004-10-12 Application filed by Wyeth Corp filed Critical Wyeth Corp

2008-10-15 Application granted granted Critical

2008-10-15 Publication of ATE409031T1 publication Critical patent/ATE409031T1/de

Links

239000000203 mixture Substances 0.000 title abstract 2
239000007939 sustained release tablet Substances 0.000 title 1
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 title 1
229960004688 venlafaxine Drugs 0.000 title 1
230000001430 anti-depressive effect Effects 0.000 abstract 1
239000000935 antidepressant agent Substances 0.000 abstract 1
229940005513 antidepressants Drugs 0.000 abstract 1
238000013265 extended release Methods 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
230000003287 optical effect Effects 0.000 abstract 1
229960002416 venlafaxine hydrochloride Drugs 0.000 abstract 1
QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Emergency Medicine (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT04765928T 2003-10-13 2004-10-12 Tablettenformulierungen von venlafaxin mit verzögerter freisetzung ATE409031T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP03256439A EP1523981A1 (de)	2003-10-13	2003-10-13	Venlafaxine-Zubereitungen mit verlängerter Freisetzung

Publications (1)

Publication Number	Publication Date
ATE409031T1 true ATE409031T1 (de)	2008-10-15

Family

ID=34354597

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04765928T ATE409031T1 (de)	2003-10-13	2004-10-12	Tablettenformulierungen von venlafaxin mit verzögerter freisetzung

Country Status (15)

Country	Link
US (1)	US20050136109A1 (de)
EP (2)	EP1523981A1 (de)
KR (1)	KR20060118481A (de)
CN (1)	CN1889939A (de)
AT (1)	ATE409031T1 (de)
AU (1)	AU2004283439A1 (de)
CA (1)	CA2546203A1 (de)
CO (1)	CO5690567A2 (de)
DE (1)	DE602004016761D1 (de)
DK (1)	DK1677776T3 (de)
EC (1)	ECSP066564A (de)
ES (1)	ES2313059T3 (de)
NO (1)	NO20062143L (de)
WO (1)	WO2005039555A1 (de)
ZA (1)	ZA200603822B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1476139B1 (de) *	2002-02-21	2017-05-17	Valeant Pharmaceuticals Luxembourg S.à.r.l.	Dosierformen mit kontrollierter freisetzung
US8323692B2 (en)	2002-02-21	2012-12-04	Valeant International Bermuda	Controlled release dosage forms
CA2507685A1 (en) *	2002-11-28	2004-06-10	Themis Laboratories Private Limited	Process for manufacturing sustained release microbeads containing venlafaxine hci
EP1473030B2 (de) †	2003-05-02	2014-05-14	Dexcel Ltd.	Tablettenzubereitung mit verlängerter Freisetzung von Venlafaxin
WO2007129329A2 (en) *	2006-05-08	2007-11-15	Jubilant Organosys Limited	Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
CN106176678A (zh)	2008-04-18	2016-12-07	因泰克制药有限公司	卡比多巴/左旋多巴胃滞留给药
EP2378883B1 (de) *	2008-12-04	2015-12-23	Intec Pharma Ltd.	Magenretentives arzneistoffabgabesystem für zaleplon
EP2726066B1 (de)	2011-06-28	2021-03-31	Neos Therapeutics, LP	Dosisformen für amphetamin zur oralen verabreichung
CN109771380A (zh) *	2017-11-10	2019-05-21	连云港恒运药业有限公司	去甲文拉法辛盐酸盐药物组合物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4535186A (en) *	1983-04-19	1985-08-13	American Home Products Corporation	2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US5530013A (en) *	1994-02-14	1996-06-25	American Home Products Corporation	Venlafaxine in the inducement of cognition enhancement
US5506270A (en) *	1995-01-30	1996-04-09	American Home Products Corporation	Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
US5554383A (en) *	1995-04-06	1996-09-10	Trustees Of Tufts College	Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
PE57198A1 (es) *	1996-03-25	1998-10-10	American Home Prod	Formula de liberacion prolongada
SE0102888D0 (sv) *	2001-08-29	2001-08-29	Astrazeneca Ab	New formulation
DE10208335A1 (de) *	2002-02-27	2003-09-04	Roehm Gmbh	Arzneiform und Verfahren zu ihrer Herstellung
AR039162A1 (es) *	2002-03-28	2005-02-09	Synthon Bv	Formulaciones de venlafaxina de liberacion extendida
AU2003226751A1 (en) *	2002-03-28	2003-10-13	Synthon B.V.	Low water-soluble venlafaxine salts
IL149055A0 (en) *	2002-04-09	2002-11-10	Karma Pharm Ltd	Extended release composition comprising as active compound venlafaxine hydrochloride
BR0311693A (pt) *	2002-06-10	2005-03-22	Wyeth Corp	Sal de formato de o-desmetil-venlafaxina

2003
- 2003-10-13 EP EP03256439A patent/EP1523981A1/de not_active Withdrawn
2004
- 2004-10-12 EP EP04765928A patent/EP1677776B1/de not_active Expired - Lifetime
- 2004-10-12 AT AT04765928T patent/ATE409031T1/de not_active IP Right Cessation
- 2004-10-12 DK DK04765928T patent/DK1677776T3/da active
- 2004-10-12 WO PCT/EP2004/011384 patent/WO2005039555A1/en not_active Ceased
- 2004-10-12 KR KR1020067009319A patent/KR20060118481A/ko not_active Withdrawn
- 2004-10-12 CN CNA2004800364996A patent/CN1889939A/zh active Pending
- 2004-10-12 ES ES04765928T patent/ES2313059T3/es not_active Expired - Lifetime
- 2004-10-12 AU AU2004283439A patent/AU2004283439A1/en not_active Abandoned
- 2004-10-12 DE DE602004016761T patent/DE602004016761D1/de not_active Expired - Fee Related
- 2004-10-12 CA CA002546203A patent/CA2546203A1/en not_active Abandoned
- 2004-10-13 US US10/964,240 patent/US20050136109A1/en not_active Abandoned
2006
- 2006-05-12 ZA ZA200603822A patent/ZA200603822B/en unknown
- 2006-05-12 CO CO06045410A patent/CO5690567A2/es not_active Application Discontinuation
- 2006-05-12 EC EC2006006564A patent/ECSP066564A/es unknown
- 2006-05-12 NO NO20062143A patent/NO20062143L/no unknown

Also Published As

Publication number	Publication date
AU2004283439A1 (en)	2005-05-06
CN1889939A (zh)	2007-01-03
US20050136109A1 (en)	2005-06-23
KR20060118481A (ko)	2006-11-23
CA2546203A1 (en)	2005-05-06
EP1677776B1 (de)	2008-09-24
DE602004016761D1 (de)	2008-11-06
DK1677776T3 (da)	2009-01-19
ZA200603822B (en)	2008-05-28
WO2005039555A1 (en)	2005-05-06
EP1677776A1 (de)	2006-07-12
EP1523981A1 (de)	2005-04-20
ECSP066564A (es)	2006-10-17
NO20062143L (no)	2006-07-07
CO5690567A2 (es)	2006-10-31
ES2313059T3 (es)	2009-03-01

Legal Events

Date	Code	Title	Description
2009-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60330909D1 (de)	2010-02-25	Tablette mit modifizierter freisetzung von bupropion hydrochlorid
CY1106929T1 (el)	2012-09-26	Κρυσταλλικες μορφες υδροχλωριδιου (-)-(1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλοπροπυλο)-φαινολης
BR0209431A (pt)	2004-08-03	Novos compostos de 4-anilinoquinolino-3-carboxamidas
NO20042807L (no)	2004-07-02	Farmasoytiske sammensetninger som innbefatter aktive vitamin D forbindelser
IS8398A (is)	2006-04-05	Lyfjasamsetningar til að meðhöndla æxli
BR0308452A (pt)	2006-06-06	composições farmacêuticas e métodos de preparação de composição farmacêutica
DK1656372T3 (da)	2013-07-01	2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme
SK4326U (sk)	2005-12-01	Farmaceutická kompozícia s predĺženým uvoľňovaním
ATE455092T1 (de)	2010-01-15	Substituierte tetracyclin-verbindungen zur behandlung von malaria
NO20033384D0 (no)	2003-07-29	Farmasöytisk formulering
CY1109880T1 (el)	2014-09-10	ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR
IS7691A (is)	2005-02-09	Lyfjasamsetningar til að meðhöndla æxli
NO20033785L (no)	2003-10-24	Farmasöytisk formulering
HN2002000198A (es)	2005-10-20	Composiciones farmaceuticas de amlodipina y atorvastatina
UY27548A1 (es)	2003-06-30	Sales de ácido succínico de 5,7,14-triazatetraciclo (10.3.1.02.11.04,9) exadeca-2 (11),3,5,7,9-pentaeno y composiciones farmacéuticas
DE602005027540D1 (de)	2011-06-01	Feste formulierungen von ospemifen
NO20035627D0 (no)	2003-12-15	Farmasöytisk formulering
ECSP044999A (es)	2004-04-28	Agentes antidiabeticos
NO20052310D0 (no)	2005-05-11	Posisjons isomerer av PEG IFN alfa 2A.
ATE409031T1 (de)	2008-10-15	Tablettenformulierungen von venlafaxin mit verzögerter freisetzung
MA31430B1 (fr)	2010-06-01	Formulation a liberation prolongee de nevirapine
DE502004005560D1 (de)	2008-01-03	Pharmazeutische formulierungen enthaltend hochreine basen von 3,3-diphenylpropylaminmonoestern
BRPI0410044A (pt)	2006-04-25	forma de dosagem contendo pantoprazol como ingrediente ativo
ATE352305T1 (de)	2007-02-15	Stabile pharmazeutische zusammensetzungen mit desloratadine
ATE389405T1 (de)	2008-04-15	Fexofenadine hydrochlorid polymorph